Johns Hopkins
Coverage of Johns Hopkins in the Nexus archive.
- SEN JEAN SHAHEEN: One immediate way Congress can ease families' insulin costs
Senator Jean Shaheen highlights the need to cap insulin costs for Americans, citing a bipartisan bill to limit monthly expenses to $35. The Inflation Reduction Act successfully reduced Medicare beneficiaries' insulin costs, but millions with private insurance still face high expenses. A Mississippi family's $194 monthly insulin cost for their young son underscores the ongoing issue.
- Opinion: We published in Nature Medicine in 2025 for free. In 2026, it cost us $12,850
In 2025, a study published in Nature Medicine had no cost despite being NIH-funded. In 2026, a similar NIH-funded study required a $12,850 open-access fee due to the 2024 NIH Public Access Policy. Both studies were results of years of work by Johns Hopkins teams.
- Anthropic adviser says it's "not hypothetical" that AI could abet biological weapons risk
Anthropic adviser Ben Buchanan and CBS News contributor Chris Krebs discussed AI regulation and the risk of AI enabling biological weapons during a segment on 'Face the Nation with Margaret Brennan.' The conversation focused on whether the government should regulate AI and the potential dangers of unaddressed AI advancements.
- Hidden driving danger when edible cannabis and alcohol mix
Combining cannabis edibles and alcohol may significantly impair drivers compared to using either substance alone, according to Johns Hopkins research. Field sobriety tests often fail to detect cannabis-related impairment in such cases.
- STAT+: In the battle of sepsis algorithms, performance alone doesn’t predict victory
A new generation of sepsis prediction algorithms is emerging, including a retooled version from Epic and a device from Bayesian Health that received FDA clearance. The previous algorithm from Epic failed to perform in real-world settings, sending too many alerts. New models are being tested in health systems.
- FDA cliffhanger: Will Marty Makary stay or go?
FDA Commissioner Marty Makary's job is uncertain after reports of his potential firing, which could impact the agency's regulatory decisions and the US economy. The FDA regulates about one-fifth of the US economy, and Makary has made significant moves during his tenure. His potential replacement could bring more predictability to the agency.